A phase II clinical trial of cediranib with olaparib in the patients with progression of ovarian cancer after PARPi treatment showed that ABCB1 upregulation is clinically important, and a poor outcome is observed if ABCB1 expression is increased [12]. Here, ABCB1 is linked to ovarian cancer.